Rheumatoid Arthritis News

In this video from ACR Convergence 2021, Kathryn Dao, MD, discusses a presentation based on a podcast, “Take a Pain Check,” for teenagers with rheumatic disease.

In this video from ACR Convergence 2021, Kathryn Dao, MD, spoke with Healio about a presentation that asked, “could RA be cured?”

Kathryn Dao, MD, spoke with Healio about the impact of the “ITIS” diet on rheumatoid arthritis, which was presented at ACR Convergence 2021.

In this video from ACR Convergence 2021, Kathryn Dao, MD, provided insight on the data from the GLORIA trial, which found that steroids improved disease activity “but at a cost.”

In this video from ACR Convergence 2021, Kathryn Dao, MD, highlighted cardiovascular risk factors to be aware of when prescribing JAK inhibitors for patients with rheumatoid arthritis.

Kathryn Dao, MD, spoke with Healio about an ACR Convergence 2021 presentation that reported that “rheumatoid arthritis patients who were cared for through telehealth actually did no worse compared to face-to-face visits.”

In this video from ACR Convergence 2021, Kathryn Dao, MD, discussed multiple presentations that investigated questions rheumatologists have had about COVID-19 since the pandemic began.

In the real-world setting, tofacitinib was not found to significantly increase risk of cardiovascular outcomes in patients with rheumatoid arthritis compared with TNF inhibitors, according to an abstract presented at ACR Convergence 2021.

In patients with rheumatoid arthritis-associated interstitial lung disease, more severe RA disease activity and impaired functional status were associated with increased mortality, according to data presented at ACR Convergence 2021.

In patients with rheumatoid arthritis, there was no significant difference in outcomes for interleukin-6 and TNF inhibitors, according to a presentation at ACR Convergence 2021.